<DOC>
	<DOCNO>NCT01151033</DOCNO>
	<brief_summary>The objective study assessment performance , safety efficacy ProNOVA XR Polymer Free Drug Eluting Stent System treatment patient de novo native coronary artery lesion .</brief_summary>
	<brief_title>A Clinical Evaluation ProNOVA XR Polymer Free Drug Eluting Coronary Stent System</brief_title>
	<detailed_description>This study prospective , single arm , multicenter registry approximately 50 patient undergoing PCI ProNOVA Drug Eluting Coronary Stent System accord Instructions Use . The purpose registry evaluation performance , safety efficacy ProNOVA XR DES real-world patient . Following initial stent implantation , patient clinical follow 30 day , 6 12 month . Additionally patient angiographic F/U 6 month assess late luminal loss QCA measurement neointimal volume include stent apposition intravascular ultrasound .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>General Patient must least 18 year age . Patient able verbally confirm understand risk , benefit treatment alternative receive ProNOVA XR DES legally authorize representative provide write informed consent prior study related procedure , approve appropriate Medical Ethics Committee respective clinical site . Patient must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) Patient must agree undergo require followup examination . Patients childbearing potential must negative pregnancy test within 7 day treatment , must nursing time treatment . Angiographic Target lesion must de novo lesion ( prior stent implant , prior brachytherapy ) Target vessel reference diameter must 2.25 mm 4.0 mm visual estimate Target lesion â‰¤ 28 mm length visual estimate Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance clinical investigation plan , confound data interpretation associate limited life expectancy ( i.e. , less one year ) Patient know hypersensitivity contraindication aspirin , either heparin bivalirudin , clopidogrel ticlopidine , cobalt , chromium , nickel , contrast sensitivity adequately premedicated Participation another device drug study complete followup phase another study within last 30 day Patients judged lesion prevents complete inflation angioplasty balloon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>ProNOVA XR Polymer Free Drug Eluting Coronary Stent System</keyword>
	<keyword>DES</keyword>
	<keyword>stent</keyword>
	<keyword>coronary artery lesion</keyword>
	<keyword>ProNOVA</keyword>
	<keyword>stent implantation</keyword>
</DOC>